DK1362600T3 - Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis - Google Patents

Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis

Info

Publication number
DK1362600T3
DK1362600T3 DK02711351T DK02711351T DK1362600T3 DK 1362600 T3 DK1362600 T3 DK 1362600T3 DK 02711351 T DK02711351 T DK 02711351T DK 02711351 T DK02711351 T DK 02711351T DK 1362600 T3 DK1362600 T3 DK 1362600T3
Authority
DK
Denmark
Prior art keywords
decoy
stat
atopic dermatitis
traps
treatment
Prior art date
Application number
DK02711351T
Other languages
Danish (da)
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of DK1362600T3 publication Critical patent/DK1362600T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02711351T 2001-02-20 2002-02-06 Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis DK1362600T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20
PCT/JP2002/000990 WO2002066070A1 (fr) 2001-02-20 2002-02-06 Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe

Publications (1)

Publication Number Publication Date
DK1362600T3 true DK1362600T3 (da) 2008-07-28

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02711351T DK1362600T3 (da) 2001-02-20 2002-02-06 Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis

Country Status (11)

Country Link
US (2) US9012417B2 (zh)
EP (2) EP1362600B1 (zh)
JP (2) JP3778357B2 (zh)
AT (1) ATE390938T1 (zh)
CY (1) CY1108165T1 (zh)
DE (1) DE60225899T2 (zh)
DK (1) DK1362600T3 (zh)
ES (1) ES2307733T3 (zh)
PT (1) PT1362600E (zh)
TW (1) TWI308492B (zh)
WO (1) WO2002066070A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340505A3 (en) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
EP1362600B1 (en) * 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
WO2004110533A1 (ja) * 2003-05-09 2004-12-23 Anges Mg, Inc. 薬剤が収容された針無注射器
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
AU2004268457A1 (en) * 2003-08-29 2005-03-10 Anges Mg, Inc. Gene therapy for skin disorders using needleless syringes
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
WO2005062854A2 (en) * 2003-12-19 2005-07-14 University Of Cincinnati Polyamides for nucleic acid delivery
CA2583413A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
CA2583576A1 (en) 2004-10-22 2006-04-27 Anges Mg, Inc. Chimera (double) decoy
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
JPWO2006132204A1 (ja) 2005-06-06 2009-01-08 アンジェスＭｇ株式会社 転写因子デコイ
WO2007013852A1 (en) * 2005-07-27 2007-02-01 Agency For Science, Technology & Research Modulators
CA2634291A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
EP1978096A1 (en) * 2005-12-22 2008-10-08 Genomidea Inc Novel oligonucleotide and nf-kappa b decoy comprising the same
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
US20100105762A1 (en) 2007-02-16 2010-04-29 Ryuichi Morishita Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
EP2266626B1 (en) * 2008-03-28 2014-06-18 AnGesMG, Inc. Composition for external application comprising transcription factor decoy as active ingredient
ES2724851T3 (es) 2012-05-10 2019-09-16 Adynxx Inc Formulaciones para el suministro de principios activos
EP3180434B1 (en) 2014-08-15 2019-07-17 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
EP1340505A3 (en) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
KR100192149B1 (ko) * 1994-10-24 1999-06-15 이시노 요시푸사 경피 투여형 제제
ES2285712T3 (es) * 1995-05-12 2007-11-16 Anges Mg, Inc. Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
KR19990071523A (ko) * 1995-11-21 1999-09-27 해리 에이. 루스제 Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법
AU731909B2 (en) * 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2001055331A (ja) * 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
EP1170363B1 (en) * 2000-02-02 2007-11-21 Kaneda, Yasufumi Virus envelope vector for gene transfer
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
EP1362600B1 (en) 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
WO2003063911A1 (fr) * 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
JPWO2002066070A1 (ja) 2004-06-17
JP2009102428A (ja) 2009-05-14
EP1362600A1 (en) 2003-11-19
PT1362600E (pt) 2008-07-09
TWI308492B (zh) 2009-04-11
JP3778357B2 (ja) 2006-05-24
DE60225899T2 (de) 2009-04-09
US20040162251A1 (en) 2004-08-19
JP4987022B2 (ja) 2012-07-25
EP1690544A3 (en) 2012-03-07
WO2002066070A1 (fr) 2002-08-29
ES2307733T3 (es) 2008-12-01
US20090105183A1 (en) 2009-04-23
EP1362600B1 (en) 2008-04-02
EP1690544B1 (en) 2017-09-13
US9012417B2 (en) 2015-04-21
DE60225899D1 (de) 2008-05-15
CY1108165T1 (el) 2014-02-12
EP1690544A2 (en) 2006-08-16
EP1362600A4 (en) 2005-09-21
ATE390938T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
DK1362600T3 (da) Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis
WO2002043652A3 (en) Anti-proliferative drugs
DE60118463D1 (de) Multi Elektrodenkatheter, System, und Anwendungsmethode
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
CY1109972T1 (el) Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
WO2005092392A3 (en) Conjugated psychotropic drugs and uses thereof
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
CY1105070T1 (el) Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
FR2868784B1 (fr) Copolymere sequence, composition le comprenant et procede de traitement cosmetique
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
CA2441461A1 (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
TNSN03065A1 (en) BIOPESTICIDE COMPOSITIONS
WO2004012652A3 (en) Treatment of multiple sclerosis with brain targeted anti oxidant compounds
DE602004018479D1 (de) Schädlingsbekämpfungsformulierung und abgabevorrichtung
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
BR0115880A (pt) Emprego de compostos ciclohexanona de 6-dimetilaminometila-1-fenil para o tratamento da incontinência urinária
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
WO2005039480A8 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT